182 related articles for article (PubMed ID: 11032416)
21. Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.
Ferreon JC; Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6591-6. PubMed ID: 19357310
[TBL] [Abstract][Full Text] [Related]
22. Structural basis of how stress-induced MDMX phosphorylation activates p53.
Chen X; Gohain N; Zhan C; Lu WY; Pazgier M; Lu W
Oncogene; 2016 Apr; 35(15):1919-25. PubMed ID: 26148237
[TBL] [Abstract][Full Text] [Related]
23. A fluorescence polarization assay for the identification of inhibitors of the p53-DM2 protein-protein interaction.
Knight SM; Umezawa N; Lee HS; Gellman SH; Kay BK
Anal Biochem; 2002 Jan; 300(2):230-6. PubMed ID: 11779115
[TBL] [Abstract][Full Text] [Related]
24. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
Lyakhovich A; Shekhar MP
Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
[TBL] [Abstract][Full Text] [Related]
25. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
Tao W; Levine AJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3077-80. PubMed ID: 10077639
[TBL] [Abstract][Full Text] [Related]
26. HDM2 negatively affects the Chk2-mediated phosphorylation of p53.
Bjørling-Poulsen M; Meek D; Issinger OG
FEBS Lett; 2005 May; 579(12):2604-8. PubMed ID: 15862297
[TBL] [Abstract][Full Text] [Related]
27. The central region of HDM2 provides a second binding site for p53.
Yu GW; Rudiger S; Veprintsev D; Freund S; Fernandez-Fernandez MR; Fersht AR
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1227-32. PubMed ID: 16432196
[TBL] [Abstract][Full Text] [Related]
28. Characterization of two peptide epitopes on Mdm2 oncoprotein that affect p53 degradation.
Balass M; Kalef E; Maya R; Wilder S; Oren M; Katchalski-Katzir E
Peptides; 2002 Oct; 23(10):1719-25. PubMed ID: 12383858
[TBL] [Abstract][Full Text] [Related]
29. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
30. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
31. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
D'Arcy P; Maruwge W; Ryan BA; Brodin B
Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
[TBL] [Abstract][Full Text] [Related]
32. Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2.
Yadahalli S; Neira JL; Johnson CM; Tan YS; Rowling PJE; Chattopadhyay A; Verma CS; Itzhaki LS
Sci Rep; 2019 Jan; 9(1):693. PubMed ID: 30679555
[TBL] [Abstract][Full Text] [Related]
33. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.
Boyd SD; Tsai KY; Jacks T
Nat Cell Biol; 2000 Sep; 2(9):563-8. PubMed ID: 10980695
[TBL] [Abstract][Full Text] [Related]
34. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers.
Craig AL; Burch L; Vojtesek B; Mikutowska J; Thompson A; Hupp TR
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):133-41. PubMed ID: 10432310
[TBL] [Abstract][Full Text] [Related]
35. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.
Unger T; Juven-Gershon T; Moallem E; Berger M; Vogt Sionov R; Lozano G; Oren M; Haupt Y
EMBO J; 1999 Apr; 18(7):1805-14. PubMed ID: 10202144
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of HDM2 and activation of p53 by ribosomal protein L23.
Jin A; Itahana K; O'Keefe K; Zhang Y
Mol Cell Biol; 2004 Sep; 24(17):7669-80. PubMed ID: 15314174
[TBL] [Abstract][Full Text] [Related]
37. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
[TBL] [Abstract][Full Text] [Related]
38. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
Liu Z; Olejniczak ET; Fesik SW
Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
[TBL] [Abstract][Full Text] [Related]
39. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2.
Sengupta S; Wasylyk B
Genes Dev; 2001 Sep; 15(18):2367-80. PubMed ID: 11562347
[TBL] [Abstract][Full Text] [Related]
40. Understanding the interaction of 14-3-3 proteins with hDMX and hDM2: a structural and biophysical study.
Srdanović S; Wolter M; Trinh CH; Ottmann C; Warriner SL; Wilson AJ
FEBS J; 2022 Sep; 289(17):5341-5358. PubMed ID: 35286747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
